GlassScriptPhysician profile
Tedi Guma
NPI 1801482930
$943.78
in general payments reported to CMS, 2019-2025
13 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $899 · 2022: $45.13.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $187.82 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $141.51 | 2021 | |
| Optinose US, INC. | $140.81 | 2021 | |
| Genzyme Corporation | $123.45 | 2021 | |
| Alk-Abello, INC | $100.56 | 2021 | |
| Amgen INC. | $64.95 | 2021 | |
| Kaleo, INC. | $61.21 | 2021 | |
| Aimmune Therapeutics, INC. | $30.18 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $20.63 | 2021 | |
| Glaxosmithkline, LLC. | $20.62 | 2021 | |
| Pfizer INC. | $17.94 | 2021 | |
| Pharming Healthcare, INC. | $17.90 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $16.20 | 2021 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tedi Guma listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.